Nisa Investment Advisors LLC Acquires 299 Shares of HealthEquity, Inc. (NASDAQ:HQY)

Nisa Investment Advisors LLC grew its stake in HealthEquity, Inc. (NASDAQ:HQY) by 8.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,719 shares of the company’s stock after acquiring an additional 299 shares during the quarter. Nisa Investment Advisors LLC’s holdings in HealthEquity were worth $357,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in HQY. Wasatch Advisors LP raised its stake in shares of HealthEquity by 6.6% in the 3rd quarter. Wasatch Advisors LP now owns 7,758,890 shares of the company’s stock valued at $635,065,000 after purchasing an additional 483,269 shares during the period. Vaughan Nelson Investment Management L.P. lifted its stake in HealthEquity by 36.7% in the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 843,423 shares of the company’s stock valued at $69,034,000 after acquiring an additional 226,563 shares in the last quarter. Barclays PLC lifted its stake in HealthEquity by 209.3% in the 3rd quarter. Barclays PLC now owns 166,492 shares of the company’s stock valued at $13,628,000 after acquiring an additional 112,667 shares in the last quarter. Thrivent Financial for Lutherans boosted its position in HealthEquity by 33.3% during the 3rd quarter. Thrivent Financial for Lutherans now owns 293,624 shares of the company’s stock worth $24,033,000 after acquiring an additional 73,404 shares during the last quarter. Finally, B. Metzler seel. Sohn & Co. Holding AG acquired a new stake in shares of HealthEquity in the third quarter valued at approximately $5,675,000. 99.55% of the stock is owned by institutional investors.

Insider Activity

In related news, Director Stuart B. Parker sold 25,000 shares of the business’s stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $96.72, for a total value of $2,418,000.00. Following the transaction, the director now owns 19,061 shares in the company, valued at $1,843,579.92. The trade was a 56.74 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Frank Corvino sold 1,039 shares of the business’s stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $96.10, for a total transaction of $99,847.90. Following the sale, the director now directly owns 3,784 shares of the company’s stock, valued at approximately $363,642.40. The trade was a 21.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 34,289 shares of company stock valued at $3,355,718. Insiders own 2.20% of the company’s stock.

Wall Street Analysts Forecast Growth

HQY has been the subject of a number of analyst reports. Mizuho began coverage on shares of HealthEquity in a research report on Wednesday, December 4th. They issued an “outperform” rating and a $126.00 target price for the company. JMP Securities increased their price objective on HealthEquity from $105.00 to $107.00 and gave the company a “market outperform” rating in a report on Tuesday, December 10th. Royal Bank of Canada boosted their target price on shares of HealthEquity from $100.00 to $105.00 and gave the stock an “outperform” rating in a report on Tuesday, December 10th. The Goldman Sachs Group began coverage on shares of HealthEquity in a research report on Friday, November 15th. They set a “neutral” rating and a $108.00 price target on the stock. Finally, Bank of America boosted their price objective on shares of HealthEquity from $100.00 to $120.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. One investment analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat.com, HealthEquity presently has an average rating of “Moderate Buy” and a consensus price target of $110.71.

HealthEquity Stock Performance

NASDAQ HQY opened at $108.80 on Thursday. The firm’s fifty day moving average price is $99.85 and its two-hundred day moving average price is $88.02. The stock has a market cap of $9.43 billion, a PE ratio of 99.82, a PEG ratio of 1.86 and a beta of 0.54. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.20 and a current ratio of 3.20. HealthEquity, Inc. has a fifty-two week low of $65.01 and a fifty-two week high of $111.36.

HealthEquity (NASDAQ:HQY) last issued its quarterly earnings data on Monday, December 9th. The company reported $0.59 earnings per share for the quarter, missing analysts’ consensus estimates of $0.71 by ($0.12). HealthEquity had a return on equity of 9.70% and a net margin of 8.41%. During the same period in the prior year, the business posted $0.40 EPS. On average, equities analysts expect that HealthEquity, Inc. will post 2.32 EPS for the current fiscal year.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.